Emvena Therapeutics
Emvena Therapeutics is developing placenta-targeted mRNA medicines for serious maternal and fetal conditions, with a lead program focused on preeclampsia. The company's investigational therapy uses specially formulated lipid nanoparticles to deliver mRNA encoding vascular endothelial growth factor directly to the placenta, aiming to restore healthy blood vessel growth and interrupt the disease cycle at its source.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
across 1 round
Founders
Founder details are not available yet.
Product
Problem
Preeclampsia affects 2-8% of pregnancies worldwide and is a leading cause of maternal and infant illness and death, with approximately 10 million cases and 70,000 maternal deaths annually. There is currently no approved therapy that addresses the underlying disease, leaving clinicians with limited options beyond symptom management and, in severe cases, premature delivery of the baby.
Solution
Emvena Therapeutics is developing an investigational therapy designed to be delivered directly to the placenta to restore healthy blood vessel growth and reestablish normal placental function. The company's technology uses specially formulated lipid nanoparticles, a drug delivery platform related to mRNA medicine technology, to preferentially deliver therapeutic payloads to the placenta. In preclinical mouse studies, the approach enabled delivery of mRNA encoding vascular endothelial growth factor to the placenta, helping reverse high blood pressure and improve measures of placental and fetal health. By restoring healthy placental vasculature, the therapy aims to interrupt the cycle of declining blood flow and rising sFlt1 levels at its source, rebalancing angiogenic and anti-angiogenic factors to improve outcomes for both mother and child.
Target Audience
Primary customers are maternal-fetal medicine specialists, obstetricians, and healthcare systems treating pregnant patients with preeclampsia, as well as clinical researchers focused on placental disorders and pregnancy complications.
Features
- Placenta-targeted lipid nanoparticle delivery platform designed to preferentially deliver mRNA therapeutics to the placenta
- Lead drug candidate delivers mRNA encoding vascular endothelial growth factor to promote new blood vessel formation in the placenta
- Mechanism of action aimed at interrupting the disease cycle by rebalancing angiogenic and anti-angiogenic factors, including reducing elevated sFlt1 levels
- Preclinical validation in murine models demonstrating reversal of high blood pressure and improved placental and fetal health measures
- Technology built on a delivery platform related to mRNA medicines, leveraging established lipid nanoparticle science